Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Autobahn Therapeutics has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in July 2024.
Autobahn Therapeutics's investors include ARCH Venture Partners, Insight Venture Management, LLC., Samsara BioCapital, Canaan Partners, Blue Owl.
Autobahn Therapeutics is headquartered in San Diego, United States.
Clinical stage biotechnology company developing restorative treatments for people affected by neuropsychiatric & neuroimmunologic disorders
Autobahn Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autobahn Therapeutics — Funding & Investors." VCBacked, July 24, 2024, https://www.vcbacked.co/company/autobahn-therapeutics. Accessed September 14, 2026.
VCBacked. (2024). Autobahn Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/autobahn-therapeutics
{{cite web |title=Autobahn Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/autobahn-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated